Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.76 |
| ▸ | NPC1 | O15118 | 10/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.76 |
| ▸ | MAPT | P10636 | 4/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 2/20 | 0.76 |
| ▸ | PKM | P14618 | 1/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9445241 | 0.90 | RAB9A (0.75) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL15183732 | 0.90 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL28007798 | 0.89 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL28003955 | 0.88 | KMT2A (0.67) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL9185209 | 0.87 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL28007803 | 0.87 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL7787088 | 0.87 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL14096496 | 0.87 | ALDH1A1 (0.70) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10939388 | 0.86 | SMN1; SMN2 (0.91) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL15183729 | 0.86 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170314007-A1 | MEDICAMENT DESIGN POCKET OF ORNITHINE DECARBOXYLASE AND APPLICATION OF MEDICAMENT DESIGN POCKET | CHINA THREE GORGES UNIVERSITY (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170314007-A1 | MEDICAMENT DESIGN POCKET OF ORNITHINE DECARBOXYLASE AND APPLICATION OF MEDICAMENT DESIGN POCKET | CHINA THREE GORGES UNIVERSITY (CN) | 2017-11-02 | — | — | US | disclosed |
| CN-104739820-A | Small molecule inhibitor and application thereof to inhibiting ornithine decarboxylase (ODC) | UNIV CHINA THREE GORGES CTGU | 2015-07-01 | — | — | CN | disclosed |
| US-6727245-B2 | 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | disclosed |
| CN-1250776-A | Heterodicyclic compound derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-04-19 | — | — | CN | disclosed |
| CN-1051548-C | Heterobicyclic derivatives, pharmaceutical compositions containing them, process for preparing them and their use | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-04-19 | — | — | CN | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| CN-1157617-A | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170314007-A1 | MEDICAMENT DESIGN POCKET OF ORNITHINE DECARBOXYLASE AND APPLICATION OF MEDICAMENT DESIGN POCKET | ODC1, PLPBP, OTC | RAB9A 4869/4885NPC1 4435/4885SMN1; SMN2 4845/4885 |
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | RAB9A 1092/4885NPC1 875/4885SMN1; SMN2 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.